Several drugmakers announced they will present new neurology data at the 2026 American Academy of Neurology (AAN) meeting, highlighting upcoming readouts across multiple disorders. UCB plans to share new clinical results from its generalized myasthenia gravis portfolio, while Cerevance will present positive Phase 2 data for solengepras in Parkinson’s disease. Lundbeck and SK Life Science also said they will showcase additional new data and analyses, including epilepsy-focused insights. Find out more details in 5 news articles below.